SML1967
N6-(4-Hydroxybenzyl) adenine riboside
≥98% (HPLC)
别名:
N-[(4-Hydroxyphenyl)methyl]adenosine, N6-(4-Hydroxybenzyl)-adenosine, NHBA, T1-11
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C17H19N5O5
化学文摘社编号:
分子量:
373.36
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
InChI
1S/C17H19N5O5/c23-6-11-13(25)14(26)17(27-11)22-8-21-12-15(19-7-20-16(12)22)18-5-9-1-3-10(24)4-2-9/h1-4,7-8,11,13-14,17,23-26H,5-6H2,(H,18,19,20)/t11-,13-,14-,17-/m1/s1
SMILES string
OC[C@H]1O[C@@H](N2C=NC3=C2N=CN=C3NCC4=CC=C(O)C=C4)[C@H](O)[C@@H]1O
InChI key
UGVIXKXYLBAZND-LSCFUAHRSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
N6-(4-Hydroxybenzyl) adenine riboside (NHBA) is an orally available and brain penetrant active active ingredient of Gastrodia elata rhizomes used for the treatment of insomnia. N6-(4-Hydroxybenzyl) adenine riboside is an adenosine A2A receptor and the equilibrative nucleoside transporter 1 (ENT1) agonist. It exhibits sedative and hypnotic effects by binding to adenosine A1 and A2A receptors in mice. N6-(4-Hydroxybenzyl) adenine riboside exerted a therapeutic effect on HD transgenic mouse by decreasing protein level of polyglutamine-expanded huntingtin in the striatum.
Orally available and brain penetrant active adenosine A2A receptors and the equilibrative nucleoside transporter 1 (ENT1) agonist
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Nai-Kuei Huang et al.
PloS one, 6(6), e20934-e20934 (2011-06-30)
Huntington's disease (HD) is a neurodegenerative disease caused by a CAG trinucleotide expansion in the Huntingtin (Htt) gene. The expanded CAG repeats are translated into polyglutamine (polyQ), causing aberrant functions as well as aggregate formation of mutant Htt. Effective treatments
Jhih-Bin Chen et al.
ChemMedChem, 6(8), 1390-1400 (2011-06-22)
A novel compound, N⁶-(4-hydroxybenzyl)adenosine, isolated from Gastrodia elata and which has been shown to be a potential therapeutic agent for preventing and treating neurodegenerative disease, was found to target both the adenosine A(2A) receptor (A(2A) R) and the equilibrative nucleoside
An-Hsun Chou et al.
Neuropharmacology, 99, 308-317 (2015-08-10)
More studies are required to develop therapeutic agents for treating spinocerebellar ataxia type 3 (SCA3), which is caused by mutant polyglutamine-expanded ataxin-3 and is the most prevalent subtype of spinocerebellar ataxias. T1-11 [N6-(4-Hydroxybenzyl) adenosine], isolated from a Chinese medicinal herb
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持